Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET is a PHASE2 clinical asset sponsored by Novartis Pharmaceuticals in Tumor Pathway Activations Inhibited by Dovitinib. SEO and diligence focus: Dovitinib (TKI258), endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.